36.8 C
Delhi
Monday, June 23, 2025

Alembic Pharma receives USFDA final approval for Prazosin Hydrochloride Capsules

Date:

Share post:

Donate-GC-Razorpay

Mumbai: Pharma major, Alembic Pharma on Wednesday said it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Minipress Capsules, 1 mg, 2 mg, and 5 mg, of Pfizer Inc. Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure. Refer to our label for full indication.

Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg have an estimated market size of US$ 50 million for twelve months ending Dec 2022, according to IQVIA.

Related articles

Mumbai Phalotsav 2025: A Green Gift to the City by Panchamahabhute Foundation

 The Panchamahabhute Foundation successfully hosted the ‘Mumbai Phalotsav 2025’, a unique and impactful free fruit-tree distribution drive, on...

How Game Theory Can Help India Counter the Global Misinformation War on Minority Atrocities

In international diplomacy and geopolitics, perception is often more potent than truth. The global narrative that India is...

Galle Test ends in draw as Shanto shines with twin tons

Galle: The opening Test between Sri Lanka and Bangladesh ended in a hard-fought draw on Saturday, with rain...

Pant joins elite club of hattrick of tons

Leeds: Rishabh Pant etched his name in the record books yet again as he struck a blistering century...